Stable fixation of an ultra-short femoral neck-preserving hip prosthesis: a 5-year RSA, DXA, and clinical prospective outcome study of 48 patients.

"Written and informed consent was obtained from all patients, who were enrolled according to the guidelines for observational studies in epidemiology (STROBE) [] and the Helsinki Declaration. The local ethics committee approved the study on February 2, 2011 (approval no. N-20100054). The study is also registered at ClinicalTrials.gov (NCT01326832). This study was co-financed by Aalborg University Hospital and Biomet Europe. Biomet Europe has manufactured the Primoris hip implant, co-financed the RSA analysis, and covered the difference in expenses between this new implant and the standard implant used in our clinic. The Primoris implant is patented (CE560346) and licensed to Zimmer Biomet Inc. None of the authors received any personal compensation from Biomet Europe. Complete disclosure of interest forms according to ICMJE are available on the article page, doi: 10.2340/17453674.2024.40074"